Effect and Predictive Elements for 52 Weeks’ Telbivudine Treatment on Naïve HBeAg positive Chronic Hepatitis B

Xiao-Feng Zhu; Li-Xia Lu; Ying Wang; Kong-wen Xu; Da-jiang Li; Xia Zhu; Li Liu; Cong Liu; Jin-Rong Wang; Hong Tang; Lichun Wang

doi:10.5812/kowsar.1735143X.795

Hepatitis Monthly

Official Journal of Research Center for Gastroenterology and Liver Diseases

Home

Current Issue All Issues In Press Articles Accepted Manuscripts Search

Instructions

Journal Information Boards and committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Reviewer and AE Registration Form Contact Us Support

APC

Authors Guide Submit Manuscript

https://doi.org/10.5812/kowsar.1735143X.795

Effect and Predictive Elements for 52 Weeks’ Telbivudine Treatment on Naïve HBeAg positive Chronic Hepatitis B

Author(s):

Xiao-Feng Zhu¹,

Li-Xia Lu²,

Ying Wang³,

Kong-wen Xu³,

Da-jiang Li⁴,

Xia Zhu⁵,

Li Liu⁵,

Cong Liu⁵,

Jin-Rong Wang⁵,

Hong Tang⁵,

Lichun Wang^4,*

1Δepidemiology Department, West China School of public Health, Sichuan University, Chengdu, China

2epidemiology Department, West China School of public Health, Sichuan University , Chengdu, China

3epidemiology Department, West China School of public Health, Sichuan University , Chengdu, China.

4Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China

5Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China.

Hepatitis Monthly:Vol. 11, issue 12; e93029

Published online:Dec 31, 2011

Article type:Research Article

Received:May 06, 2019

Accepted:Dec 31, 2011

How to Cite:Xiao-Feng ZhuLi-Xia LuYing WangKong-wen XuDa-jiang LiXia ZhuLi LiuCong LiuJin-Rong WangHong TangLichun Wanget al.Effect and Predictive Elements for 52 Weeks’ Telbivudine Treatment on Naïve HBeAg positive Chronic Hepatitis B.Hepat Mon.11(12):e93029.https://doi.org/10.5812/kowsar.1735143X.795.

Abstract

Background: Antiviral treatment with nucleoside analogs has been used for chronic hepatitis B (CHB). each kind of nucleoside analog has its own characteristics and suitability for patients. Telbivudine (LdT, brand name: Sebivo, Beijing novartis pharma Ltd) is the newest nucleoside analog, with strong and rapid viral suppression. However, its resistance rate is relatively high during long-term application, due to low genetic barriers to resistance. So, it is necessary to increase the effect and reduce resistance with effective management, according to baseline factors and early on-treatment responses. Objectives: To reveal possible predictive factors of the effect of telbivudine (LdT) treatment on naïve HBeAg-positive chronic hepatitis B (CHB) patients to optimize treatment. Patients and Methods: A total 71 naïve chronic hepatitis B (CHB) patients who met the inclusion criteria were enrolled. All patients were treated with LdT 600 mg Qd for at least 52 weeks. Multiple logistic regression analyses were done to investigate the predictive values of baseline factors and responses at Week 24. Results: The reduction in hepatitis virus B (HBV) DnA level was 6.44 ± 2.38 lg copies/mL at Week 52 compared with baseline. The complete virus response (CVR), biochemical response (BR), serological response (SR), and drug resistance (DR) were 61.99%, 77.46%, 35.21%, and 8.45% respectively. By multiple regression analysis, baseline alanine aminotransferase (ALT) levels significantly affected CVR (P = 0.024, oR = 1.008), and baseline ALT and baseline HBV DnA levels were independent compact factors of SR (P = 0.012, oR = 1.007; P = 0.001, oR = 0.423). The differences in CVR, SR, and DR in patients with ALT > 120 Iu/mL compared with patients with ALT ≤ 120 Iu/mL were statistically significant. The differences in SR in patients with HBV DnA > 107 copies/mL compared with patients with HBV DnA ≤ 107 copies/mL were statistically significant. Additionally, CVR, BR, and SR were differed significantly between patients with HBV DnA lower than 300 copies/mL at Week 24 and patients with HBV DnA higher than 300 copies/mL (P = 0.000, P = 0.0016, and P = 0.000, respectively). Conclusions: There were more responders among naïve HBeAg-positive chronic hepatitis B patients with lower HBV DnA levels (especially lower than 107 copies/mL) and higher ALT values (especially higher than 120 Iu/mL at baseline) to LdT treatment. Adjustments for treatment strategy should be considered if HBV DnA > 300 copies/mL at Week 24 is observed.

Keywords

Telbivudine

Hepatitis B

Chronic

Predictive Value of Tests

Alanine Transaminase

Hepatitis B Virus

References

1.
The references are available in the PDF file.

comments

Crossmark

Checking

Share on

Comments

Number of Comments:0

Cited by

Metrics

Get Permission (article level)

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Xiao-Feng Zhu:[PubMed][Scholar]
Li-Xia Lu:[PubMed][Scholar]
Ying Wang:[PubMed][Scholar]
Kong-wen Xu:[PubMed][Scholar]
Da-jiang Li:[PubMed][Scholar]
Xia Zhu:[PubMed][Scholar]
Li Liu:[PubMed][Scholar]
Cong Liu:[PubMed][Scholar]
Jin-Rong Wang:[PubMed][Scholar]
Hong Tang:[PubMed][Scholar]
Lichun Wang:[PubMed][Scholar]